The technology is said to be superior at identifying cell types in human blood, providing faster and more reliable assessments for clinical decision making
The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus
The partnership aims to co-market exosome technology as well as the joint development of new exosome based products
The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity
Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, aims to provide accurate results in less than 15 minutes
Agreements with AstraZeneca and the University of Nebraska Medical Center showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis
The agreement is part of preparations for GMP production of material for the first clinical study of CG01
Watch this on-demand webinar to discover the critical factors when choosing an assay for coronavirus testing
New research published in Nature Immunology show strong T cell responses in patients recovered from COVID-19
CDx approval expands clinical utility of Oncomine Dx Target Test to identify candidates for GAVRETO
New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus
Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections
Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021
Read this application note to discover how T cell activation assays can help accelerate COVID-19 vaccine development
Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method
A new prognostic tool developed by an international team led by CTI-Bath paves the way for personalized medicine for cancer patients
Watch this on-demand webinar to learn about the latest approaches in single nucleus transcriptomics and ATAC-Seq
Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions
FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and multiple genomic signatures to inform treatment decisions for all solid tumor cancers
Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus
Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%
The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
